Loading...
01/11 03:34
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call shows mixed signals: a slight increase in revenue, reduced SG&A expenses, and a decrease in net loss for Q3, but an increase in net loss over nine months. The Q&A reveals positive progress in trials but lacks transparency in patient enrollment numbers. The strategic plan highlights potential partnerships and regulatory approvals, which could be positive. However, the absence of market cap data and the lack of immediate strong catalysts lead to a neutral outlook for short-term stock movement.
Research and Development (R&D) Expenses Increased to $936,000 in Q3 2025 from $931,000 in Q3 2024, and to $3.8 million for the 9 months ended September 2025 from $3.0 million for the same period in 2024. The increase was driven by the closeout of the CardiAMP Heart Failure study, statistical data analysis, new enrollment in the CardiAMP Heart Failure II trial, and regulatory activities for potential approvals.
Selling, General, and Administrative (SG&A) Expenses Decreased to $0.6 million in Q3 2025 from $0.8 million in Q3 2024, and to $2.4 million for the 9 months ended September 2025 from $2.8 million for the same period in 2024. The decrease was primarily due to lower compensation expenses and lower professional service fees, coupled with reduced share-based compensation expenses.
Net Loss Decreased to $1.5 million for Q3 2025 from $1.7 million in Q3 2024. However, it increased to $6.2 million for the 9 months ended September 2025 from $5.5 million for the same period in 2024. The changes reflect variations in operational costs and financing activities.
Net Cash Used in Operations Decreased to $1.5 million in Q3 2025 from $1.7 million in Q3 2024, and to $4.9 million for the 9 months ended September 2025 from $5.5 million for the same period in 2024. The decrease was due to improved operational efficiencies.
Cash on Hand Ended Q3 2025 with $5.3 million in cash, reflecting a $6 million September financing and 304,000 shares of stock sold during the quarter under the company's ATM program. This cash is expected to provide runway into Q2 2026 without additional financing.
CardiAMP cell therapy: Received FDA breakthrough designation and has shown promise in treating ischemic heart failure. Actively enrolling in the CardiAMP Heart Failure II clinical study. Positive preliminary consultation with Japan's PMDA, with potential market entry in Japan. CardiAMP system is already approved in Japan for orthopedic applications.
CardiALLO allogeneic mesenchymal stem cell therapy: Off-the-shelf cell therapy being advanced in a Phase I/II trial for inflammatory ischemic heart failure. Potential for conditional approval in Japan based on trial results.
Helix Biotherapeutic Delivery System: Supports therapeutic agent programs and partners. Preparing a de novo 510(k) submission for FDA approval.
Heart 3D Fusion Imaging: Partnership with CART-Tech to develop imaging solutions for biotherapeutic delivery and cardiac biopsy. Promising results in animal studies, with clinical advancement planned for 2026.
Japan market expansion: Positive consultation with Japan's PMDA for CardiAMP system. Japan's aging population and limited heart failure treatment options make it a key market.
R&D expenses: Increased to $936,000 in Q3 2025 from $931,000 in Q3 2024, driven by CardiAMP Heart Failure study closeout and new trial enrollment.
SG&A expenses: Decreased to $0.6 million in Q3 2025 from $0.8 million in Q3 2024, primarily due to lower compensation expenses.
Net loss: Reduced to $1.5 million in Q3 2025 from $1.7 million in Q3 2024. Cash on hand expected to last until Q2 2026.
Funding strategy: Pursuing nondilutive funding for CardiALLO trial and pathways to fund CardiAMP Heart Failure II study to completion.
Regulatory strategy: Engaging with FDA and PMDA for approvals of CardiAMP and Helix systems. Preparing for FDA submission for Helix system in Q4 2025.
Regulatory Approvals: The company faces inherent uncertainties in developing new products and obtaining regulatory approvals, which could delay market entry and impact financial performance.
Clinical Trials: The CardiAMP Heart Failure II trial is still in progress, and its success is critical for the company's future. Delays or negative outcomes could adversely affect strategic objectives.
Funding Challenges: The company is pursuing pathways for nondilutive funding to complete trials, but lack of funding clarity could hinder progress.
Market Entry in Japan: While there is potential for approval in Japan, the process is still ongoing, and any delays or negative outcomes could impact the company's expansion plans.
Operational Costs: Research and development expenses have increased, and while selling, general, and administrative expenses have decreased, the company still faces financial pressures.
Cash Runway: The company has cash to operate only until the second quarter of 2026, necessitating additional financing to sustain operations.
CardiAMP System Approvals: BioCardia anticipates submitting for approval of the CardiAMP system for market entry in Japan following a positive consultation with Japan's PMDA. A meeting with the FDA on the approvability of the CardiAMP system is also expected in Q4 2025.
CardiAMP Heart Failure II Trial: The confirmatory Phase 3 trial is accelerating with active enrollment at four centers and additional centers being onboarded. The trial aims to validate the efficacy of the CardiAMP system using a composite primary outcome measure.
BCDA-02 CardiAMP Therapy for Chronic Myocardial Ischemia: BioCardia plans to seek peer-reviewed publication of positive trial results in Q1 2026, which showed significant improvements in exercise tolerance and reduction in angina episodes.
BCDA-03 CardiALLO Therapy: The company expects clarity on nondilutive funding for the Phase I/II trial in Q1 2026. Positive results could enable submission for conditional approval in Japan.
Helix Biotherapeutic Delivery System: BioCardia plans to submit for FDA approval of the Helix system in Q4 2025, which could enhance regulatory support for CardiAMP programs.
Heart 3D Fusion Imaging: The company intends to advance Heart 3D fusion imaging to clinical trials in 2026, following promising results in animal studies.
The selected topic was not discussed during the call.
The earnings call shows mixed signals: a slight increase in revenue, reduced SG&A expenses, and a decrease in net loss for Q3, but an increase in net loss over nine months. The Q&A reveals positive progress in trials but lacks transparency in patient enrollment numbers. The strategic plan highlights potential partnerships and regulatory approvals, which could be positive. However, the absence of market cap data and the lack of immediate strong catalysts lead to a neutral outlook for short-term stock movement.
The earnings call reveals mixed signals. Financial performance shows increased net loss and cash usage, which are negative. However, there are ongoing advancements in trials and partnerships, which are positive. The Q&A highlights uncertainties around regulatory approvals and partnerships, but also potential growth opportunities. The neutral sentiment reflects this balance of positive developments against financial challenges and uncertainties.
The earnings call reveals financial challenges, including a significant net loss, increased expenses, and a low cash position. While there are potential partnerships and regulatory progress, the failure to meet primary endpoints in trials and competitive market pressures raise concerns. The Q&A session shows management's vague responses on key issues, adding to uncertainty. Despite some positive aspects, such as modest financing and ongoing trials, the overall sentiment is negative due to financial instability and regulatory risks.
The earnings call summary suggests a negative outlook due to several factors: increasing net losses, low cash reserves, and high financial risks. The Q&A section shows management's vague responses and lack of clarity on strategic timelines, which may raise investor concerns. Despite ongoing partnerships and potential regulatory approvals, the financial health and competitive pressures overshadow these positives. The market's reaction is likely negative due to financial instability and uncertainties in achieving key milestones.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
